Cerenis: Corporate Presentation (Cerenis) - Nov 6, 2016 - "Primary endpoint (reduction in plaque at 12 mg/kg dose vs. placebo) not achieved"; "Reduction in the total volume of atherosclerosis vs. baseline was statistically significant at 3 mg/kg"
P2 data • Dyslipidemia
|